Search

everythinglearnresearchcommunity

for

Search:↓

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

Treating psoriasis on the scalp, nails, and skin folds is challenging, often requiring systemic treatments for severe cases, with some success in topical and biologic treatments.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

More research is needed to find the best treatment for dissecting cellulitis of the scalp.

New treatments focusing on immune pathways show promise for stubborn hair loss.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Discoid Lupus Erythematosus often causes scarring hair loss, is influenced by genetics and environment, and requires early treatment to prevent worsening.

Hidradenitis Suppurativa is likely an autoinflammatory disease, and better understanding its causes could improve treatments.

Combination therapies may be more effective for treating Folliculitis Decalvans than antibiotics alone.

This special edition focuses on the unique aspects of treating skin conditions in women, including during pregnancy and in diverse populations like women of color and transgender patients.

Psoriasis increases annual healthcare costs by $4,044 per patient, with biologic treatments costing significantly more than phototherapy.

Metabolic syndrome is linked to skin diseases, requiring integrated treatment and monitoring.

A patient got a skin reaction on their hands and feet after using secukinumab for psoriasis.

Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.

New acne treatments show promise as alternatives to traditional therapies.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Microneedles show promise for improving hair regrowth in alopecia.

Certain medications, including some immune drugs, contraceptives, and hair loss treatments, are often linked to hair loss.

TNF-alpha inhibitors can cause various immune-related skin issues.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Imuvert can prevent some chemotherapy-induced hair loss.